XML 182 R128.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative arrangements and non-collaborative arrangement transactions                      
Total revenues from anti-CD20 therapeutic programs $ 2,852.6 $ 3,376.1 $ 3,681.6 $ 3,534.3 $ 3,671.3 $ 3,600.1 $ 3,616.7 $ 3,489.8 $ 13,444.6 $ 14,377.9 $ 13,452.9
Revenues from anti-CD20 therapeutic programs                      
Collaborative arrangements and non-collaborative arrangement transactions                      
Total revenues from anti-CD20 therapeutic programs $ 419.0 $ 560.1 $ 478.3 $ 520.4 $ 600.8 $ 595.8 $ 576.4 $ 517.4 1,977.8 2,290.4 1,980.2
Genentech                      
Collaborative arrangements and non-collaborative arrangement transactions                      
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses                 1,080.2 1,542.4 1,431.9
Other revenues from anti-CD20 therapeutic programs                 $ 897.6 $ 748.0 $ 548.3